Daniel Margolis, MD
Professor of Radiology, Weill Cornell Medical College
As Professor of Radiology in the Abdominal Imaging section and Director of Prostate MRI, I oversee all clinical aspects of prostate magnetic resonance imaging as they relate to the detection and characterization of prostate cancer for targeted biopsy, surgery and radiation planning, treatment follow-up, and active surveillance. This has resulted in multiple publications demonstrating the effectiveness of prostate MRI for clinical management. Our experience has resulted in my appointment to the American College of Radiology Prostate Imaging Reporting and Data Systems steering committee as well as invited lectures at the Society of Abdominal Radiology, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America, as well as lectures abroad. Having completed the K30 Graduate Training Program in Translational Investigation at UCLA, I provide expertise in clinical trial design incorporating medical imaging in addition to designing the imaging protocol itself. I collaborate with our physicists at Cornell and have collaborated with physicists and engineers at UCLA and affiliated institutions in the development of new and innovative pulse sequences and image post-processing. Additionally, as Chair of the Institutional Review Board, I provide guidance towards successful activation of ethically designed human subjects research. In the past decade, I authored over 150 publications and have participated in multiple NIH projects (2 R01 and R24 as co-investigator, Key personal of Clinical and Translational Science Award from the NIH).
Financial relationships
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Promaxo, IncTopic:Prostate MRIDate added:06/03/2024Date updated:06/03/2024Relationship end date:03/25/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Guerbet, IncTopic:Contrast MediaDate added:06/03/2024Date updated:06/03/2024Relationship end date:06/06/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:Stratagen BioTopic:Quantitative MRIDate added:06/03/2024Date updated:06/03/2024Relationship end date:06/01/2026